Oral Tranexamic Acid Dosing for Melasma
For melasma treatment in patients with normal renal function and no contraindications, start with oral tranexamic acid 250 mg twice daily (500 mg/day total) for 12 weeks, which can be increased to 250 mg three times daily (750 mg/day total) if needed for optimal response.
Evidence-Based Dosing Recommendations
The most rigorous evidence comes from a 2023 network meta-analysis that directly compared different oral tranexamic acid doses for melasma 1. This analysis determined that 750 mg per day (250 mg three times daily) for 12 consecutive weeks represents the optimal dose-response balance, though 250 mg twice daily (500 mg/day) remains an acceptable option for patients with adherence concerns 1.
Starting Dose Strategy
- Initial dose: 250 mg twice daily (500 mg/day total)
- Duration: 12 weeks minimum
- Titration option: Can increase to 250 mg three times daily (750 mg/day) if response is suboptimal after 4-8 weeks
A 2023 head-to-head randomized trial comparing 500 mg/day versus 1000 mg/day found both regimens achieved significant MASI score reductions (58.86% and 50.88% respectively) with no statistically significant difference between groups 2. This supports starting with the lower dose to minimize potential adverse effects while maintaining efficacy.
Alternative Dosing Ranges
Multiple studies demonstrate efficacy across a range of doses 3, 4:
- Low dose: 250 mg twice daily (500 mg/day) - effective and well-tolerated 4
- Standard dose: 250 mg three times daily (750 mg/day) - optimal per network meta-analysis 1
- Higher doses: 500 mg twice daily (1000 mg/day) or 500 mg three times daily (1500 mg/day) - show efficacy but without clear superiority over lower doses 3
Treatment Duration and Maintenance
Treat for 12 weeks initially, then reassess. The 2023 randomized trial found that improvements achieved at 12 weeks remained stable during 12 weeks of follow-up without maintenance therapy, with minimal relapse rates 2. This suggests not all patients require tapering or maintenance dosing.
Recent 2025 Delphi consensus by international experts recommends oral tranexamic acid as an alternative to topical therapies, emphasizing its role in comprehensive melasma management 5.
Critical Safety Considerations
Absolute Contraindications
- Active thromboembolic disease or history of thrombosis
- Recent thrombotic event (within 3 months)
- Pregnancy or breastfeeding
- Severe renal impairment (see dose adjustments below)
- Subarachnoid hemorrhage history 6
Relative Contraindications
- Atrial fibrillation
- Known thrombophilia
- Concurrent use of hormonal contraceptives (increases thrombotic risk) 7, 6
- Concurrent use of Factor IX concentrates or other prothrombotic agents 6
Renal Dose Adjustments
For patients with renal impairment, FDA labeling provides specific guidance 6:
- Serum creatinine 1.36-2.83 mg/dL: Reduce to twice daily dosing
- Serum creatinine 2.83-5.66 mg/dL: Reduce to once daily dosing
- Serum creatinine >5.66 mg/dL: Give every 48 hours or half-dose daily
Tranexamic acid is 90% renally excreted, making dose reduction essential in renal dysfunction to avoid neurotoxicity and ocular toxicity 8.
Monitoring and Adverse Effects
Common side effects include 1, 2, 3:
- Gastrointestinal upset (mild stomach discomfort, nausea)
- Menstrual irregularities (decreased menstrual flow)
- Skin irritation (if using concurrent topical therapies)
No routine laboratory monitoring is required for patients with normal baseline renal function and no thrombotic risk factors. However, baseline assessment should document absence of contraindications.
Adjunctive Therapy Considerations
The 2025 guideline on autologous platelet concentrates notes that tranexamic acid is listed among topical therapies for melasma, and that melasma should be managed as a chronic condition with effective home care and sun protection 9. Broad-spectrum photoprotection is essential and should be emphasized regardless of pharmacologic treatment chosen 5.
Studies comparing intradermal PRP versus tranexamic acid injections found PRP showed higher efficacy, though both were effective 9. However, oral tranexamic acid offers the advantage of convenience and systemic action without procedural requirements.
Clinical Pearls
- Start low, go slow: Begin with 500 mg/day to assess tolerance before escalating
- Time to response: Expect visible improvement by 4-8 weeks, with continued improvement through 12 weeks 2, 10
- Inflammation marker correlation: Recent 2025 data suggests NLR and HDL levels may predict treatment response, though this requires validation 10
- Route flexibility: If oral therapy is not tolerated, topical 5% tranexamic acid cream twice daily shows comparable efficacy (50.88% MASI reduction) 11
- Maintenance: Most patients maintain improvement without ongoing therapy, though melasma is chronic and may require retreatment 2, 5